Clinical case of long-term disease control in a patient with EGFR-positive non-small cell lung cancer

Lung cancer remains the leading cause of cancer-related deaths both in Russia and worldwide, it is often diagnosed at a late stage and the median survival with traditional first-line chemotherapy platinum-based regimens does not exceed one year. The discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene offered first opportunity for personalized treatment of advanced non-small cell lung cancer. Currently, molecular testing for patients with advanced-stage lung adenocarcinoma is a routine activity, the use of targeted agents has become the standard of the 1st line of therapy, the treatment strategy after disease progression based not only on the RECIST radiological criteria, but also on the dynamics of clinical symptoms and the identification of a possible mechanism of resistance. The clinical case below demonstrates safe and long-term control of the disease in patient receiving target agents treatment, features of evaluation the effectiveness of the treatment, and also illustrates the advantages of the strategy of continued therapy with asymptomatic progression of the disease.

1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660.

2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98. https://doi.org/10.1056/NEJMoa011954.

3. Mazza V., Cappuzzo F. Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib. Appl Clin Genet. 2017;10:49-56. https://doi.org/10.2147/TACG.S103471.

4. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. https://doi.org/10.1056/NEJMoa040938.

5. Westover D., Zugazagoitia J., Cho B.C., Lovly C.M., Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(Suppl. 1):i10-i19. https://doi.org/10.1093/annonc/mdx703.

6. Thongprasert S., Duffield E., Saijo N., Wu Y.L., Yang J.C., Chu D.T. et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011;6(11):1872-1880. https://doi.org/10.1097/JTO.0b013e31822adaf7.

7. Chen G., Feng J., Zhou C., Wu Y.L., Liu X.Q., Wang C. et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol. 2013;24(6):1615-1622. https://doi.org/10.1093/annonc/mdt012.

8. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957. https://doi.org/10.1056/NEJMoa0810699.

9. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246. https://doi.org/10.1016/S1470-2045(11)70393-X.

10. Kobayashi S., Boggon TJ., Dayaram T., Janne P.A., Kocher O., Meyerson M. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefi-tinib. N Engl J Med. 2005;352(8):786-792. https://doi.org/10.1056/NEJMoa044238.

11. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73. https://doi.org/10.1371/journal.pmed.0020073.

12. Lee J.W., Soung Y.H., Kim S.Y., Nam S.W., Park W.S., Wang Y.P. et al. ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Cancer Lett. 2006;237(1):89-94. https://doi.org/10.1016/j.canlet.2005.05.026.

13. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W. et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528-538. https://doi.org/10.1016/S1470-2045(12)70087-6.

14. Mok T.S., Wu Y.L., Ahn M.J., Garassino M.C., Kim H.R., Ramalingam S.S. et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629-640. https://doi.org/10.1056/NEJMoa1612674.

15. Soria J.C., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee K.H. et al. Osimertinib in Untreated EGFR-Mutated Advanced NonSmall-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125. https://doi.org/10.1056/NEJMoa1713137.

16. Ramalingam S.S., Vansteenkiste J., Planchard D., Cho B.C., Gray J.E., Ohe Y. et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41-50. https://doi.org/10.1056/NEJMoa1913662.

17. Goto Y., Tanai C., Yoh K., Hosomi Y., Sakai H., Kato T. et al. Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open. 2017;2(4):e000214. https://doi.org/10.1136/esmoopen-2017-000214.

18. Papadimitrakopoulou V.A., Mok T.S., Han J.Y., Ahn M.J., Delmonte A., Ramalingam S.S. et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31(11):1536-1544. https://doi.org/10.1016/j.annonc.2020.08.21001.